NCT01029821

Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

Low-Molecular-Weight Heparin for DVT Prophylaxis After Open Reduction and Internal Fixation of Ankle Fractures: A Randomized, Prospective Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: University of Tennessee · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

1. The use of LMWH following open reduction and internal fixation of ankle fractures will reduce the number of thrombi formed. 2. The rates of clinically significant DVT will be equivalent between two groups.

Detailed description

Routine use of thromboprophylaxis may be over treatment and definitely increases healthcare costs. While prophylaxis may reduce the number of thrombi formed the exact number and clinical significance of these is unknown. This study seeks to answer the question of whether or not DVT prophylaxis with low-molecular-weight heparin (LMWH) following ORIF of ankle fractures is warranted.

Conditions

• Deep Venous Thrombosis

Interventions

Type	Name	Description
DRUG	Low-Molecular-Weight Heparin	Isolated Ankle Fracture Single planned operation

Timeline

• Start date: 2010-02-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2009-12-10
• Last updated: 2011-06-16

Locations

1 site across 1 country: United States